National STD Diagnostic and Therapy Center, Department of Dermatology, Venereology and Dermato-oncology, Semmelweis University, Mária u. 41, 1085, Budapest, Hungary.
Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1423-6. doi: 10.1007/s10096-013-1892-y. Epub 2013 May 18.
The aim of this study was to examine the incidence and antibiotic sensitivity of Ureaplasma urealyticum and Mycoplasma hominis strains cultured from the genital discharges of sexually active individuals who attended our STD outpatient service. Samples were taken with universal swab (Biolab®, Budapest, Hungary) into the Urea-Myco DUO kit (Bio-Rad®, Budapest, Hungary) and incubated in ambient air for 48 h at 37 °C. The determination of antibiotic sensitivity was performed in U9 and arginin broth using the SIR Mycoplasma kit (Bio-Rad®, Budapest, Hungary) under the same conditions. Between 01.05.2008 and 31.12.2011, 373/4,466 (8.35 %) genito-urethral samples with U. urealyticum and 41/4,466 (0.91 %) genito-urethral samples with M. hominis infection were diagnosed in sexually active individuals in the National STD Center, Semmelweis University. U. urealyticum was isolated in 12.54 % in the cervix and 4.1 % in the male urethra, while M. hominis was isolated in 1.33 % in the cervix and 0.51 % in the male urethra. The affected age group was between 21 and 60 years old. U. urealyticum strains were sensitive to tetracycline (95.9 %), doxycycline (97.32 %), and azithromycin (85.79 %), and resistant to erythromycin (81.23 %), clindamycin (75.06 %), and ofloxacin (25.2 %). Cross-resistance occurred in 38.71 % of patients to erythromycin and clindamycin. M. hominis strains were sensitive to clindamycin, ofloxacin, and doxycycline in more than 95 %, to tetracycline in 82.92 %, and no cross-resistance was detected among the antibiotics. Our study confirms that the continuously changing antibiotic resistance of ureaplasmas and mycoplasmas should be followed at least in a few centers in every country, so as to determine the best local therapy options for sexually transmitted infection (STI) patients.
本研究旨在检测在参加性传播疾病门诊服务的性活跃个体的生殖器分泌物中培养的解脲支原体和人型支原体菌株的发生率和抗生素敏感性。使用通用拭子(Biolab ® ,布达佩斯,匈牙利)将样本采集到 Urea-Myco DUO 试剂盒(Bio-Rad ® ,布达佩斯,匈牙利)中,并在 37°C 下的环境空气中孵育 48 小时。在相同条件下,使用 SIR 支原体试剂盒(Bio-Rad ® ,布达佩斯,匈牙利)在 U9 和精氨酸肉汤中进行抗生素敏感性测定。在 2008 年 5 月 1 日至 2011 年 12 月 31 日期间,在国家性传播疾病中心,塞梅尔维斯大学,从性活跃个体的 373/4466(8.35%)泌尿生殖道样本中诊断出解脲支原体感染,从 41/4466(0.91%)泌尿生殖道样本中诊断出人型支原体感染。解脲支原体在宫颈中的分离率为 12.54%,在男性尿道中的分离率为 4.1%,而人型支原体在宫颈中的分离率为 1.33%,在男性尿道中的分离率为 0.51%。受影响的年龄组在 21 至 60 岁之间。解脲支原体菌株对四环素(95.9%)、强力霉素(97.32%)和阿奇霉素(85.79%)敏感,对红霉素(81.23%)、克林霉素(75.06%)和氧氟沙星(25.2%)耐药。38.71%的患者对红霉素和克林霉素有交叉耐药性。人型支原体菌株对克林霉素、氧氟沙星和强力霉素的敏感性超过 95%,对四环素的敏感性为 82.92%,并且未检测到抗生素之间的交叉耐药性。我们的研究证实,至少在每个国家的几个中心,应持续监测脲原体和支原体不断变化的抗生素耐药性,以确定治疗性传播感染(STI)患者的最佳本地治疗方案。